Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
01 June 2004Website:
http://www.angiodynamics.comNext earnings report:
12 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:02:22 GMTDividend
Analysts recommendations
Institutional Ownership
ANGO Latest News
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (PE). “The CE Mark represents a major.
Despite strength in the Med Tech business, AngioDynamics (ANGO) registers overall soft performance in third-quarter fiscal 2024.
AngioDynamics (ANGO) announces the FDA's approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
AngioDynamics Inc. (NASDAQ:ANGO ) Q3 2024 Earnings Conference Call April 4, 2024 8:00 AM ET Company Participants Jim Clemmer - President, Chief Executive Officer Steve Trowbridge - Executive Vice President, Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer & Co. John Young - Canaccord Genuity Operator Good morning and welcome to the AngioDynamics fiscal year 2024 third quarter earnings call. At this time, all participants are in a listen-only mode.
AngioDynamics (ANGO) announces its settlement agreement with BD's affiliate, C.R. Bard, to resolve a 10-year dispute over outstanding patent litigation.
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market open on Thursday, April 4, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to.
In the most recent trading session, AngioDynamics (ANGO) closed at $5.37, indicating a -0.74% shift from the previous trading day.
In the most recent trading session, AngioDynamics (ANGO) closed at $5.67, indicating a -1.39% shift from the previous trading day.
What type of business is AngioDynamics?
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
What sector is AngioDynamics in?
AngioDynamics is in the Healthcare sector
What industry is AngioDynamics in?
AngioDynamics is in the Medical Instruments & Supplies industry
What country is AngioDynamics from?
AngioDynamics is headquartered in United States
When did AngioDynamics go public?
AngioDynamics initial public offering (IPO) was on 01 June 2004
What is AngioDynamics website?
https://www.angiodynamics.com
Is AngioDynamics in the S&P 500?
No, AngioDynamics is not included in the S&P 500 index
Is AngioDynamics in the NASDAQ 100?
No, AngioDynamics is not included in the NASDAQ 100 index
Is AngioDynamics in the Dow Jones?
No, AngioDynamics is not included in the Dow Jones index
When does AngioDynamics report earnings?
The next expected earnings date for AngioDynamics is 12 July 2024